MICB and neoplasm: Soluble major histocompatibility complex (MHC) class I and homologue ligands (MICA and MICB) inhibit NKG2D‐mediated killing by immune cells.[4] Therefore, to overcome these issues, it is important to identify the appropriate methods for killing tumor cells and increasing the immunogenicity of tumor antigens.